Baxter Travenol Laboratories, Inc.

Baxter International Inc.

Jan W Garber

Robert J Przybelski

John D Blue

Paul E Measells

Henry M Gajewski

Richard G Buckles

Janet C Gonder

Gary R Marchand

De Wayne Davisson

Kathleen N Stern

Barry H Vernick

Low doses of stroma-free diaspirin cross-linked hemoglobin are administered to patients undergoing hemodialysis, to achieve hemostabilization and avoid hypotensive episodes in susceptible patients. Hemoglobin therapy when implemented prophylactically in hemodialysis also partially obviates the need for further interventions to control circulatory system instability.

Hemoglobin therapy in hemodialysis

A blood bag comprises a plastic polyvinyl chloride formulation in which the polyvinyl chloride formulation contains from 5 to 30 percent by weight of a first plasticizer material which is essentially nonextractable by blood plasma stored in the bag up to 35 days at about 4.degree. C.; and from 10 to 25 percent by weight of a second plasticizer which is significantly extracted by blood plasma stored in the bag up to 35 days at about 4.degree. C.

Blood storage container and material

A method of storing a quantity of red blood cells uses a blood bag which comprises a plastic polyvinyl chloride formulation which contains from 5 to 30 percent by weight of a first plasticizer material which is essentially nonextractable by blood plasma stored in the bag up to 35 days at about 4.degree. C.; and from 10 to 25 percent by weight of a second plasticizer which is significantly extracted by blood plasma stored in the bag up to 35 days at about 4.degree. C. and which, upon leaching, is capable of suppressing the formation of plasma hemoglobin.

Method of storing red blood cells which minimizes both red blood cell

Blood may be stored in vitro for a period of days at a reduced temperature in the container which also includes a sufficient quantity of an emulsion of anti-hemolytic agent to cause a reduction in the hemolysis of the stored blood, when compared with blood under similar storage conditions to the absence of the emulsion. Preferably, the emulsion may include a fatty ester containing at least two ester linkages each comprising a fatty hydrocarbon group, with the emulsion containing sufficient hemo-compatible surfactant to stabilize the emulsion.

Anti-hemolytic agent emulsions

Blood may be stored in vitro for a period of days at a reduced temperature in the container which also includes a sufficient quantity of an emulsion of anti-hemolytic agent to cause a reduction in the hemolysis of the stored blood, when compared with blood under similar storage conditions to the absence of the emulsion. Preferably, the emulsion includes a fatty ester containing at least two ester linkages each comprising a fatty hydrocarbon group, emulsified with sufficient hemo-compatible surfactant to stabilize the emulsion.

Anti-hemolytic agent emulsions and the use thereof

A blood collection system which comprises several blood compatible sealed bags connected together by blood compatible conduits. Means for separating cryoprecipitate from blood plasma are provided. This separation is made by a filtering means. The filtering means is positioned in the outlet of one of the bags of the system. After the blood cells have been removed by a prior step, the remaining blood plasma is collected in the bag which has the filtering means in the outlet. In this bag, the blood plasma is frozen and then slowly thawed. Factor VIII rich cryoprecipitate forms in this bag as part of the freezing and thawing process. As the plasma melts, it flows from the bag through the filtering means. The filtering means positioned in the outlet of the bag retains the cryoprecipitate. Thus, the separation of Factor VIII rich cryoprecipitate from the blood plasma is effected.

Growing community of inventors

Barrington, IL, United States of America

Jan W Garber